Dose escalation study of carboplatin-pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer.
暂无分享,去创建一个
I. Kawase | T. Hirashima | K. Asami | M. Tamiya | A. Tamiya | S. Atagi | H. Suzuki | T. Tsuji | T. Kawaguchi | T. Shiroyama | N. Okamoto | N. Morishita | M. Kanazu | A. Hirooka | K. Okishio
[1] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[2] F. Fossella,et al. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first‐line treatment of advanced nonsmall cell lung carcinoma (TAX 326) , 2005, Cancer.
[3] I. Okamoto,et al. Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer. , 2010, Lung cancer.
[4] G. Giles,et al. Increasing underrepresentation of elderly patients with advanced colorectal or non‐small‐cell lung cancer in chemotherapy trials , 2006, Internal medicine journal.
[5] B. Milleron,et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial , 2011, The Lancet.
[6] G. Luporini,et al. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. , 1999, Journal of the National Cancer Institute.
[7] M. Vangel,et al. O-49 Age-specific subanalysis of ECOG 1594: Fit elderly patietns (70–80 yrs) with NSCLC do as well as younger patients (<70) , 2003 .
[8] Johan Vansteenkiste,et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] C. Gridelli,et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. , 2012, The Lancet. Oncology.
[10] M. Socinski,et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). , 2007, Chest.
[11] L. Siu,et al. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A. Rossi,et al. Lung cancer in the elderly. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] C. Coltman,et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.
[14] A. Ruano-Raviña,et al. Analysis of the relationship between p53 immunohistochemical expression and risk factors for lung cancer, with special emphasis on residential radon exposure. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] A. Rossi,et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. , 2003, Journal of the National Cancer Institute.
[16] Cockcroft Dw,et al. Prediction of Creatinine Clearance from Serum Creatinine , 1976 .
[17] A. Rossi,et al. Challenges treating older non-small cell lung cancer patients. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] N. Saijo,et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] David Cella,et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. , 2002, Journal of the National Cancer Institute.
[20] O. Brodin,et al. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .
[21] K. Kelly,et al. Comparison of Platinum-Based Chemotherapy in Patients Older and Younger than 70 Years: An Analysis of Southwest Oncology Group Trials 9308 and 9509 , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[22] J. Holland,et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] C. Stevens,et al. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). , 2007, Chest.
[24] M. Fukuoka,et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] G. Scagliotti,et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. , 2009, The oncologist.
[26] V. Lorusso,et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.